EA202190820A1 - Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты - Google Patents

Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты

Info

Publication number
EA202190820A1
EA202190820A1 EA202190820A EA202190820A EA202190820A1 EA 202190820 A1 EA202190820 A1 EA 202190820A1 EA 202190820 A EA202190820 A EA 202190820A EA 202190820 A EA202190820 A EA 202190820A EA 202190820 A1 EA202190820 A1 EA 202190820A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antiandrogens
treatment
prostate cancer
resistant prostate
metastatic castration
Prior art date
Application number
EA202190820A
Other languages
English (en)
Russian (ru)
Inventor
Исан Чэнь
Original Assignee
Арагон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49293921&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202190820(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Арагон Фармасьютикалз, Инк. filed Critical Арагон Фармасьютикалз, Инк.
Publication of EA202190820A1 publication Critical patent/EA202190820A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
EA202190820A 2012-09-26 2013-09-23 Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты EA202190820A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261705900P 2012-09-26 2012-09-26

Publications (1)

Publication Number Publication Date
EA202190820A1 true EA202190820A1 (ru) 2021-10-29

Family

ID=49293921

Family Applications (3)

Application Number Title Priority Date Filing Date
EA202190820A EA202190820A1 (ru) 2012-09-26 2013-09-23 Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
EA201890598A EA037806B1 (ru) 2012-09-26 2013-09-23 Способ лечения неметастатического кастрационно-резистентного рака простаты
EA201590650A EA030128B1 (ru) 2012-09-26 2013-09-23 Способ лечения неметастатического кастрационно-резистентного рака простаты

Family Applications After (2)

Application Number Title Priority Date Filing Date
EA201890598A EA037806B1 (ru) 2012-09-26 2013-09-23 Способ лечения неметастатического кастрационно-резистентного рака простаты
EA201590650A EA030128B1 (ru) 2012-09-26 2013-09-23 Способ лечения неметастатического кастрационно-резистентного рака простаты

Country Status (36)

Country Link
US (8) US9884054B2 (enExample)
EP (3) EP2900224A1 (enExample)
JP (4) JP6351597B2 (enExample)
KR (3) KR102210825B1 (enExample)
CN (4) CN104661658A (enExample)
AU (4) AU2013323861C1 (enExample)
BR (1) BR112015006705A8 (enExample)
CA (1) CA2885415C (enExample)
CL (1) CL2015000715A1 (enExample)
CR (1) CR20150140A (enExample)
CY (1) CY1123716T1 (enExample)
DK (1) DK3305285T3 (enExample)
EA (3) EA202190820A1 (enExample)
EC (1) ECSP15011764A (enExample)
ES (1) ES2836424T3 (enExample)
GT (1) GT201500071A (enExample)
HK (1) HK1212221A1 (enExample)
HR (1) HRP20201721T1 (enExample)
HU (1) HUE051211T2 (enExample)
IL (3) IL312316A (enExample)
IN (1) IN2015DN02387A (enExample)
LT (1) LT3305285T (enExample)
MX (2) MX379847B (enExample)
MY (1) MY180834A (enExample)
NI (1) NI201500042A (enExample)
NZ (3) NZ745682A (enExample)
PE (1) PE20150765A1 (enExample)
PH (3) PH12018502570B1 (enExample)
PT (1) PT3305285T (enExample)
RS (1) RS60976B1 (enExample)
SG (3) SG10201902568YA (enExample)
SI (1) SI3305285T1 (enExample)
SM (1) SMT202000573T1 (enExample)
UA (3) UA129494C2 (enExample)
WO (1) WO2014052237A1 (enExample)
ZA (1) ZA201808499B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012009453A (es) 2010-02-16 2012-11-23 Aragon Pharmaceuticals Inc Moduladores del receptor de androgenos y usos de los mismos.
HK1199246A1 (en) 2011-12-16 2015-06-26 奥乐玛药物股份有限公司 Novel benzopyran compounds, compositions and uses thereof
DK3305285T3 (da) 2012-09-26 2020-10-26 Aragon Pharmaceuticals Inc Anti-androgener til behandlingen af ikke-metastatisk kastrationsresistent prostatakræft
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
AU2015358497B2 (en) 2014-12-05 2021-04-29 Aragon Pharmaceuticals, Inc. Anticancer compositions
CR20170216A (es) 2014-12-05 2017-08-30 Aragon Pharmaceuticals Inc Composiciones anticancerígenas
CN115837010B (zh) * 2014-12-05 2025-03-14 阿拉贡药品公司 抗癌组合物
KR101718226B1 (ko) 2015-08-05 2017-03-20 울산대학교 산학협력단 사쿠라소사포닌 화합물을 유효성분으로 포함하는 안드로겐 수용체 관련 질환의 예방 또는 치료용 조성물
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CA3031705A1 (en) * 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Treatment of prostate cancer with niraparib
WO2019078920A1 (en) 2017-10-16 2019-04-25 Aragon Pharmaceuticals, Inc. ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC RESISTANT PROSTATE CANCER
BR112021014969A2 (pt) 2019-01-30 2021-10-05 Aragon Pharmaceuticals, Inc. Antiandrogênios para o tratamento de câncer de próstata metastático sensível à castração
US11723898B2 (en) * 2019-11-04 2023-08-15 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE550650A (enExample) 1955-08-30
JPS4916937B1 (enExample) 1970-01-21 1974-04-25
US3823240A (en) 1970-10-06 1974-07-09 Rhone Poulenc Sa Fungicidal hydantoin derivatives
GB1472467A (en) 1974-04-19 1977-05-04 Wyeth John & Brother Ltd Thiohydantoins
FR2329276A1 (fr) 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
DE2614831A1 (de) 1976-04-06 1977-10-20 Bayer Ag 1,3,4-thiadiazolylderivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
MC1220A1 (fr) 1977-10-28 1979-07-20 Hoffmann La Roche Nouveaux derives d'imidazolidine
IL55774A (en) 1977-10-28 1982-04-30 Sparamedica Ag Pharmaceutical compositions containing urea derivatives,certain such novel derivatives and their manufacture
AU531493B2 (en) 1977-12-01 1983-08-25 The Wellcome Foundation Limited Thiohydantion derivatives
EP0004723A1 (en) 1978-03-30 1979-10-17 Beecham Group Plc Deoxyhydantoins, processes for their preparation and pharmaceutical compositions containing them
FR2449448B1 (fr) 1979-02-20 1983-05-27 Inst Nat Radio Elements Composition pharmaceutique comprenant un derive de phenylhydantoine, derives mis en oeuvre et leur preparation
FI801184A7 (fi) 1979-04-24 1981-01-01 F Hoffmann La Roche & Co Menetelmä imidatsolidiini-johdannaisten valmistamiseksi.
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
JPS57197268A (en) 1981-05-29 1982-12-03 Sumitomo Chem Co Ltd Substituted phenylhydantoin derivative, its preparation, and herbicide containing the same as active ingredient
DE3382406D1 (de) 1982-04-08 1991-10-17 Shell Int Research Neue hydantoine, ihre herstellung und verwendung.
US4473393A (en) 1982-08-06 1984-09-25 Buffalo Color Corporation Pesticidal thiohydantoin compositions
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
JPS59210083A (ja) 1983-05-13 1984-11-28 Otsuka Chem Co Ltd １，３，４−チアジアゾ−ル−５−オン誘導体、その製造法及び該誘導体を有効成分とする除草剤
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
JPS6092285A (ja) 1983-10-26 1985-05-23 Shionogi & Co Ltd イソオキサゾ−ル系環状尿素類
JPS6098878U (ja) 1983-12-10 1985-07-05 リズム時計工業株式会社 液晶表示装置
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
JPS60239737A (ja) 1984-05-14 1985-11-28 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
JPH0219363Y2 (enExample) 1985-07-31 1990-05-29
US5011692A (en) 1985-12-28 1991-04-30 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
DE3604042A1 (de) 1986-02-08 1987-08-13 Hoechst Ag Imidazolidin(thi)on-derivate, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
JPS649978A (en) 1987-07-02 1989-01-13 Shionogi & Co Perfluoroalkylisoxazole derivative
US4859228A (en) 1987-07-16 1989-08-22 Ici Americas Inc Novel 5-aminomethylene-2,4-imidazolidinediones and 5-aminomethylene-2-thionoimidazolidine-4-ones
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
FR2619381B1 (fr) 1987-08-13 1989-12-08 Roussel Uclaf Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
CA1331757C (en) 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
US5614620A (en) 1988-03-30 1997-03-25 Arch Development Corporation DNA binding proteins including androgen receptor
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US6307030B1 (en) 1988-04-15 2001-10-23 The University Of North Carolina At Chapel Hill Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions
JPH0219363A (ja) 1988-07-06 1990-01-23 Fujisawa Pharmaceut Co Ltd イミダゾリジン誘導体
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE3835168A1 (de) 1988-10-15 1990-04-19 Bayer Ag N-aryl-stickstoffheterocyclen, mehrere verfahren zu ihrer herstellung und ihre verwendung als herbizide
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
FR2656302B1 (fr) 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
JP2845384B2 (ja) 1991-11-14 1999-01-13 キヤノン株式会社 画像処理装置
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5346913A (en) 1992-05-26 1994-09-13 Rohm And Haas Company N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
DE4316542C1 (de) 1993-05-18 1994-07-21 Schaefer Micomed Gmbh Osteosynthesevorrichtung
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2715402B1 (fr) 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
CA2181358A1 (en) 1994-01-21 1995-07-27 Nancy M. Gray Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US6124211A (en) 1994-06-14 2000-09-26 Fsi International, Inc. Cleaning method
JPH089997A (ja) 1994-06-28 1996-01-16 Shimadzu Corp 核酸合成法およびそれに用いる試薬キット
DE69519921T2 (de) 1994-07-29 2001-06-13 Suntory Limited, Osaka Imidazolidin-derivate und ihre verwendung
FR2725206B1 (fr) 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
DE19540027A1 (de) 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
FR2741346B1 (fr) 1995-11-16 1997-12-19 Roussel Uclaf Nouveau procede de preparation de derives phenylimidazolidine
FR2741342B1 (fr) 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
TW418195B (en) 1995-11-28 2001-01-11 American Home Prod 2-thioxo-imidazolidin-4-one derivatives
WO1997019931A1 (en) 1995-11-28 1997-06-05 American Home Products Corporation 2-(substituted sulfanyl)-3,5-dihydro-imidazol-4-one derivatives
US5554607A (en) 1995-11-28 1996-09-10 American Home Products Corporation Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of atherosclerosis
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
FR2742749B1 (fr) 1995-12-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques
US6489163B1 (en) 1996-05-08 2002-12-03 Board Of Regents, The University Of Texas System Ribozyme mediated inactivation of the androgen receptor
JP3697320B2 (ja) 1996-06-20 2005-09-21 株式会社日立製作所 光ファイバセンサ
CN1216636C (zh) 1996-08-30 2005-08-31 派普泰克有限公司 肽缓释组合物
US5726061A (en) 1996-10-08 1998-03-10 Smithkline Beechum Corporation Method of diagnosing and monitoring colorectal cancer
US7053263B2 (en) 1996-10-15 2006-05-30 The Regents Of The University Of California Mouse models of human prostate cancer progression
WO1998033772A1 (en) 1997-02-03 1998-08-06 Dow Agrosciences Llc 2-methoxyimino-2-(pyridinyloxymethyl)phenyl acetamides with carboxylic acid derivatives on the pyridine ring as fungicides
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6506607B1 (en) 1997-12-24 2003-01-14 Millennium Pharmaceuticals, Inc. Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer
WO1999065494A1 (en) 1998-06-15 1999-12-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
ATE384048T1 (de) 1998-09-22 2008-02-15 Astellas Pharma Inc Cyanophenyl-derivate
ATE240944T1 (de) 1998-09-22 2003-06-15 Degussa Verfahren zur herstellung von imidazolidin-2,4- dionen
WO2000026195A1 (en) 1998-10-30 2000-05-11 G.D. Searle & Co. Novel amino acid heterocyclic amide derivatives useful as nitric oxide synthase inhibitors
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
AU2847200A (en) 1999-01-27 2000-08-18 G.D. Searle & Co. Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors
WO2001007048A1 (en) 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
US6479063B2 (en) 1999-12-27 2002-11-12 Kenneth Weisman Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
DE60032640T2 (de) 2000-05-31 2007-10-04 Mitsui Chemicals, Inc. Schwefelverbindung und ihre verwendung
CA2411671C (en) 2000-05-31 2007-06-05 Tanabe Seiyaku Co., Ltd Inhibitors of alpha l beta 2 mediated cell adhesion
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2002053155A1 (en) 2000-12-30 2002-07-11 Geron Corporation Telomerase inhibitor
FR2823209B1 (fr) 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
US6710037B2 (en) 2001-05-01 2004-03-23 Schering Corporation Method of treating androgen-dependent disorders
WO2003029245A1 (en) 2001-10-01 2003-04-10 Bristol-Myers Squibb Company Spiro-hydantoin compounds useful as anti-inflammatory agents
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
GB0200283D0 (en) 2002-01-08 2002-02-20 Smithkline Beecham Plc Compounds
DE10218963A1 (de) 2002-04-27 2003-11-20 Aventis Pharma Gmbh Zubereitungen zur topischen Applikation von antiandrogen wirksamen Substanzen
TW200407324A (en) 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
EP1576131A4 (en) 2002-08-15 2008-08-13 Genzyme Corp EXPRESSION PATTERN IN BRAIN DENTHELIC CELLS
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
FR2845385B1 (fr) 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
FR2845384B1 (fr) 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
AU2003284005B2 (en) 2002-10-03 2009-12-17 Forest Laboratories Holdings Limited Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
AU2003279442A1 (en) 2002-10-04 2004-04-23 Laboratoires Fournier S.A. 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
UA79504C2 (en) 2002-11-07 2007-06-25 Organon Nv Indols for treating diseases associated with androgen receptors
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
JP2004252175A (ja) 2003-02-20 2004-09-09 Kyocera Mita Corp 現像装置、画像形成装置および現像剤の回収方法
EP1632477B1 (en) 2003-06-12 2017-03-01 Astellas Pharma Inc. Benzamide derivative or salt thereof
JP4664814B2 (ja) 2003-06-12 2011-04-06 中外製薬株式会社 イミダゾリジン誘導体
WO2004111031A1 (en) 2003-06-12 2004-12-23 Novo Nordisk A/S Pyridinyl carbamates as hormone-sensitive lipase inhibitors
PE20050444A1 (es) 2003-10-31 2005-08-09 Takeda Pharmaceutical Compuestos de piridina como inhibidores de la peptidasa
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
AU2004298604B2 (en) 2003-12-15 2010-09-23 The Regents Of The University Of California Molecular signature of the PTEN tumor suppressor
ATE502298T1 (de) 2003-12-19 2011-04-15 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
NZ550102A (en) 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
MXPA06010542A (es) 2004-03-15 2007-03-28 Ptc Therapeutics Inc Derivados de carbolina tetra-ciclica para la inhibicion de angiogenesis.
EP1621539A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621536A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
US7803826B2 (en) 2004-08-03 2010-09-28 Chugai Seiyaku Kabushiki Kaisha Imidazolidine derivatives
CA2579886A1 (en) 2004-09-09 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Novel imidazolidine derivative and use thereof
EP1807058A1 (en) 2004-09-10 2007-07-18 Nitec Pharma Ag Tablets with site time-controlled gastrointestinal release of active ingredient
AR053690A1 (es) 2005-03-23 2007-05-16 Pfizer Prod Inc Terapia de cancer de prostata con anticuerpos contra ctla4 y terapia hormonal
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
KR102713358B1 (ko) 2005-05-13 2024-10-02 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
FR2889189A1 (fr) 2005-07-28 2007-02-02 Cerep Sa Composes derives d'hydantoine et leur utilistion en tant qu'antagonistes de mchr-1
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
CN101032486B (zh) 2006-03-08 2011-05-11 张宏 逆转唑类药物抗真菌活性多药耐药性的药用植物增效剂
CN101032483B (zh) 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
EP2656841B1 (en) 2006-03-27 2016-08-10 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
NZ572374A (en) 2006-03-29 2011-12-22 Univ California Diarylthiohydantoin compounds
EP1891964A1 (en) 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP2063963A2 (en) 2006-08-25 2009-06-03 Cougar Biotechnology, Inc. Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent
CN104306977A (zh) 2006-08-25 2015-01-28 库伽尔生物科技公司 治疗癌症的方法和组合物
EP1905439A1 (en) 2006-09-24 2008-04-02 GPC Biotech AG Second line treatment of metastatic hormone refractory prostate cancer using satraplatin
JP4993996B2 (ja) 2006-10-20 2012-08-08 フクダ電子株式会社 輸液ポンプモニタリング装置
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
TW201716385A (zh) 2007-10-26 2017-05-16 加州大學董事會 二芳基乙內醯脲類化合物
BRPI0820338A2 (pt) 2007-11-09 2017-05-02 Novartis Ag corticosteroides para tratar a diarreia induzida por epotilona ou derivado da epotilona
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
US20140187641A1 (en) * 2012-08-23 2014-07-03 Gtx Estrogen receptor ligands and methods of use thereof
ES2535466T3 (es) 2009-02-24 2015-05-11 Medivation Prostate Therapeutics, Inc. Compuestos específicos de diariltiohidantoína
CN102413831B (zh) * 2009-04-29 2014-06-04 拜耳知识产权有限责任公司 取代的咪唑并喹喔啉
MX2012009453A (es) 2010-02-16 2012-11-23 Aragon Pharmaceuticals Inc Moduladores del receptor de androgenos y usos de los mismos.
PT2538785T (pt) 2010-02-24 2018-05-09 Medivation Prostate Therapeutics Llc Processos para a síntese de compostos de diariltiohidantoína e diarilhidantoína
US9132105B2 (en) * 2010-08-04 2015-09-15 Pellficure Pharmaceuticals, Inc. Treatment of prostate carcinoma
US20130253035A1 (en) * 2010-08-16 2013-09-26 Duke University Camkk-beta as a target for treating cancer
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2012142208A1 (en) 2011-04-13 2012-10-18 The Trustees Of The University Of Pennsylvania Bifunctional akr1c3 inhibitors/androgen receptor modulators and methods of use thereof
WO2012145330A1 (en) 2011-04-18 2012-10-26 The University Of British Columbia Fluorene-9-bisphenol compounds and methods for their use
WO2012158884A1 (en) * 2011-05-17 2012-11-22 Takeda Pharmaceutical Company Limited Pharmaceutical compositions and methods for treating cancer
PL2739153T3 (pl) 2011-07-29 2019-04-30 Medivation Prostate Therapeutics Llc Leczenie raka sutka
EP2744773B1 (en) * 2011-08-19 2016-11-02 British Columbia Cancer Agency Branch Fluorinated bisphenol ether compounds and methods for their use
US20130079241A1 (en) * 2011-09-15 2013-03-28 Jianhua Luo Methods for Diagnosing Prostate Cancer and Predicting Prostate Cancer Relapse
PL2785349T5 (pl) * 2011-11-30 2023-01-30 Astrazeneca Ab Kombinacja do leczenia nowotworu
WO2013126581A1 (en) 2012-02-24 2013-08-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonism and prostate cancer
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
FR2989357B1 (fr) 2012-04-12 2016-02-05 Allia Conditionnement unique pour un ensemble sanitaire comprenant une cuvette de wc suspendu et un bati-support associe
EA201992010A1 (ru) 2012-06-07 2020-01-24 Арагон Фармасьютикалз, Инк. Кристаллическая форма а 4-[7-(6-циано-5-трифторметилпиридин-3-ил)-8-оксо-6-тиоксо-5,7-диазаспиро[3.4]окт-5-ил]-2-фтор-n-метилбензамида для лечения заболевания или состояния, связанного с активностью андрогенных рецепторов, включая рак простаты
EP4450130A3 (en) 2012-09-11 2025-01-08 Medivation Prostate Therapeutics LLC Formulations of enzalutamide
DK3305285T3 (da) 2012-09-26 2020-10-26 Aragon Pharmaceuticals Inc Anti-androgener til behandlingen af ikke-metastatisk kastrationsresistent prostatakræft
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
WO2014175852A1 (en) 2013-04-23 2014-10-30 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
JP2014239737A (ja) 2013-06-11 2014-12-25 株式会社ジェイテクト 個人認証装置および車両用個人認証システム
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
CA2932106A1 (en) 2013-12-06 2015-06-11 F. Hoffmann-La Roche Ag Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
EA201891397A1 (ru) 2014-02-05 2019-03-29 Лек Фармасьютикалз Д.Д. Твердые фармацевтические композиции антагонистов рецепторов андрогенов
CR20170216A (es) 2014-12-05 2017-08-30 Aragon Pharmaceuticals Inc Composiciones anticancerígenas
CN115837010B (zh) 2014-12-05 2025-03-14 阿拉贡药品公司 抗癌组合物
AU2015358497B2 (en) 2014-12-05 2021-04-29 Aragon Pharmaceuticals, Inc. Anticancer compositions
CN104857157A (zh) 2015-05-12 2015-08-26 四川金堂海纳生物医药技术研究所 一种治疗子宫内膜增殖症的汤剂药物及制备方法
WO2019078920A1 (en) * 2017-10-16 2019-04-25 Aragon Pharmaceuticals, Inc. ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC RESISTANT PROSTATE CANCER
JP7085410B2 (ja) 2018-06-01 2022-06-16 太 小林 テープ巻取り用治具及び小巻テープ
BR112021014969A2 (pt) 2019-01-30 2021-10-05 Aragon Pharmaceuticals, Inc. Antiandrogênios para o tratamento de câncer de próstata metastático sensível à castração
CN119230570A (zh) 2023-06-29 2024-12-31 三星电子株式会社 图像传感器

Also Published As

Publication number Publication date
BR112015006705A2 (pt) 2017-07-04
NZ705815A (en) 2018-08-31
WO2014052237A1 (en) 2014-04-03
AU2018206695B2 (en) 2020-07-02
EP3777845A1 (en) 2021-02-17
MX371020B (es) 2020-01-13
ES2836424T3 (es) 2021-06-25
US20190269668A1 (en) 2019-09-05
IL312316A (en) 2024-06-01
SG10201902568YA (en) 2019-04-29
NI201500042A (es) 2015-09-02
US20190269667A1 (en) 2019-09-05
DK3305285T3 (da) 2020-10-26
JP6527621B2 (ja) 2019-06-05
CN115737643A (zh) 2023-03-07
US20180318277A1 (en) 2018-11-08
PT3305285T (pt) 2020-11-24
BR112015006705A8 (pt) 2019-08-27
UA117663C2 (uk) 2018-09-10
US10849888B2 (en) 2020-12-01
CL2015000715A1 (es) 2015-12-11
CN109999036A (zh) 2019-07-12
US10799489B2 (en) 2020-10-13
US20140088129A1 (en) 2014-03-27
JP2018150365A (ja) 2018-09-27
EA037806B1 (ru) 2021-05-24
EA201590650A1 (ru) 2015-07-30
KR20150070192A (ko) 2015-06-24
IL237692A0 (en) 2015-05-31
SMT202000573T1 (it) 2020-11-10
KR20220025231A (ko) 2022-03-03
EP3305285B1 (en) 2020-09-02
HUE051211T2 (hu) 2021-03-01
EA201890598A2 (ru) 2018-07-31
US10052314B2 (en) 2018-08-21
AU2020244431A1 (en) 2020-10-29
RS60976B1 (sr) 2020-11-30
US10799488B2 (en) 2020-10-13
MY180834A (en) 2020-12-10
USRE50642E1 (en) 2025-10-21
UA124967C2 (uk) 2021-12-22
JP2019163288A (ja) 2019-09-26
AU2024204555A1 (en) 2024-07-18
HK1252867A1 (en) 2019-06-06
MX2015003909A (es) 2016-01-08
JP2015531373A (ja) 2015-11-02
PH12018502570B1 (en) 2023-03-10
AU2018206695A1 (en) 2018-08-02
PE20150765A1 (es) 2015-05-15
JP7198310B2 (ja) 2022-12-28
UA129494C2 (uk) 2025-05-14
GT201500071A (es) 2015-12-31
PH12018502569A1 (en) 2020-12-07
CN104661658A (zh) 2015-05-27
JP6896016B2 (ja) 2021-06-30
SI3305285T1 (sl) 2021-03-31
CN109908114A (zh) 2019-06-21
ECSP15011764A (es) 2016-01-29
CA2885415A1 (en) 2014-04-03
PH12018502570A1 (en) 2020-12-07
JP2021130718A (ja) 2021-09-09
USRE49353E1 (en) 2023-01-03
MX2019010098A (es) 2019-10-15
CR20150140A (es) 2015-06-11
IL237692B2 (en) 2024-07-01
KR102210825B1 (ko) 2021-02-01
EA030128B1 (ru) 2018-06-29
HRP20201721T1 (hr) 2021-02-19
EP2900224A1 (en) 2015-08-05
CA2885415C (en) 2021-06-29
PH12015500615A1 (en) 2015-05-11
AU2013323861A1 (en) 2015-04-02
SG11201501870RA (en) 2015-04-29
IL237692B1 (en) 2023-08-01
NZ745682A (en) 2019-09-27
SG10201912719TA (en) 2020-02-27
PH12015500615B1 (en) 2019-02-20
NZ744456A (en) 2019-09-27
CY1123716T1 (el) 2022-03-24
EA201890598A3 (ru) 2019-03-29
LT3305285T (lt) 2020-12-10
KR20210013342A (ko) 2021-02-03
AU2013323861C1 (en) 2024-05-02
HK1212221A1 (en) 2016-06-10
AU2018206695C1 (en) 2020-10-22
JP6351597B2 (ja) 2018-07-04
AU2013323861B2 (en) 2018-04-19
EP3305285A1 (en) 2018-04-11
US20210000812A1 (en) 2021-01-07
IN2015DN02387A (enExample) 2015-09-04
IL304337A (en) 2023-09-01
ZA201808499B (en) 2022-12-21
US20180110764A1 (en) 2018-04-26
US9884054B2 (en) 2018-02-06
MX379847B (es) 2025-03-11

Similar Documents

Publication Publication Date Title
IL289300A (en) Combination therapy for treating cancer
IL288181A (en) Cancer treatment methods
EA202190820A1 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
IL224370B (en) Combination treatment for prostate carcinoma
HUE047198T2 (hu) Fitokannabinoidok emlõrák kezelésére
HUE048876T2 (hu) Rákos megbetegedések kezelése
PL2739153T3 (pl) Leczenie raka sutka
BR112014007603A2 (pt) métodos de tratamento do câncer
HRP20190046T1 (hr) Kombinirana terapija za liječenje raka
HUE046667T2 (hu) Rák kombinatív kezelése
IL226246A0 (en) Methods of treating cancer
EP2830633A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
EP2867376A4 (en) TARGETED METHODS KNOWN AS RNA-SEQ AND MATERIALS FOR THE DIAGNOSIS OF PROSTATE CANCER
LT2914254T (lt) Kombinacinės terapijos chemoresistencinių vėžių gydymui
KR102082363B9 (ko) 난소암의 치료를 위한 조합 치료
SMT201600235B (it) Predittori per il trattamento del cancro
EP2885429A4 (en) DIAGNOSTIC MARKERS FOR INDOLENT PROSTATE CANCER
IL237229A0 (en) Methods of treating cancer using lipoplatin
DK2908823T3 (da) Fremgangsmåder til behandling af cancer